Grace Therapeutics, Inc.
GRCE
$3.21
$0.103.12%
NASDAQ
06/30/2025 | 03/31/2025 | ||||
---|---|---|---|---|---|
Revenue | -- | -- | |||
Total Other Revenue | -- | -- | |||
Total Revenue | -- | -- | |||
Cost of Revenue | -- | -- | |||
Gross Profit | -- | -- | |||
SG&A Expenses | 37.83% | 2.58% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | -- | -- | |||
Total Operating Expenses | -2.86% | -14.12% | |||
Operating Income | 2.86% | 14.12% | |||
Income Before Tax | -780.10% | 91.97% | |||
Income Tax Expenses | -- | -68.26% | |||
Earnings from Continuing Operations | -628.62% | 115.31% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | -628.62% | 115.31% | |||
EBIT | 2.86% | 14.12% | |||
EBITDA | 2.86% | 14.13% | |||
EPS Basic | -558.91% | 112.74% | |||
Normalized Basic EPS | -667.44% | 93.35% | |||
EPS Diluted | -558.91% | 112.74% | |||
Normalized Diluted EPS | -667.44% | 93.35% | |||
Average Basic Shares Outstanding | 15.14% | 20.20% | |||
Average Diluted Shares Outstanding | 15.14% | 20.20% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |